Neko Scaling Beyond Self Pay

The main constraint on Neko’s growth is that its current product fits one very specific customer and care model, affluent consumers paying out of pocket for a yearly screening visit. Moving past that means changing who pays, not just adding more clinics. In Sweden, the UK, and now the U.S., Neko has shown demand for a one hour scan plus blood work plus clinician review, but each new market brings different pricing, reimbursement, licensing, and referral workflows that make expansion operationally heavier than simple clinic rollout.1 2 3 4 5

• New buyer types change the sales motion. Self pay is a direct consumer purchase, but employer, insurer, and health system channels require proof that the scan lowers downstream costs or catches issues early enough to matter. That is the jump peers like Function Health and Forward also face as they move from premium wellness into broader care pathways.1 6 7 8
• New geographies change both price and compliance. Neko currently operates across Sweden, the UK, and the U.S., with market specific pricing of SEK 2,750, £299, and $499, and its U.S. buildout already involves HSA and FSA eligibility, local clinic launch work, and state by state regulatory planning tied to FDA regulated devices.2 3 4 5 9
• Additional clinical applications are what turn a premium checkup into a bigger healthcare platform. Today the product is a bundled preventive visit. To reach reimbursed care or more medical buyer segments, Neko needs evidence that its sensor stack is useful for specific conditions and follow up pathways, not just broad health screening.1 4 9

The next phase is less about opening another flagship and more about proving that Neko’s measurement system belongs inside mainstream care budgets. If the company can tie its scan to employer benefits, insurer reimbursement, and condition specific use cases, it can move from a niche consumer service into a much larger diagnostics and preventive care market.1 2 6 9